MX2012003514A - Metodos para tratamiento de inflamaciones. - Google Patents

Metodos para tratamiento de inflamaciones.

Info

Publication number
MX2012003514A
MX2012003514A MX2012003514A MX2012003514A MX2012003514A MX 2012003514 A MX2012003514 A MX 2012003514A MX 2012003514 A MX2012003514 A MX 2012003514A MX 2012003514 A MX2012003514 A MX 2012003514A MX 2012003514 A MX2012003514 A MX 2012003514A
Authority
MX
Mexico
Prior art keywords
methods
mif
treating inflammation
cxcr2
cxcr4
Prior art date
Application number
MX2012003514A
Other languages
English (en)
Inventor
Christian Weber
Joshua Robert Schultz
Benedikt Vollrath
Alma Zernecke
Court Turner
Jurgen Bernhagen
Sergio Duron
Original Assignee
Carolus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc
Publication of MX2012003514A publication Critical patent/MX2012003514A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan aquí, en algunas realizaciones, métodos para tratar un trastorno mediado por MIF. En algunas realizaciones, el método comprende administrar un agente que inhibe (i) el enlazamiento de MIF a CXCR2 y CXCR4 y/o (ii) la activación por MIF de CXCR2 y CXCR4; (iii) la capacidad del MIF para formar un homomultímero; o una combinación de los mismos.
MX2012003514A 2009-09-23 2010-09-23 Metodos para tratamiento de inflamaciones. MX2012003514A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24521409P 2009-09-23 2009-09-23
US31903910P 2010-03-30 2010-03-30
PCT/US2010/050047 WO2011038149A2 (en) 2009-09-23 2010-09-23 Methods of treating inflammation

Publications (1)

Publication Number Publication Date
MX2012003514A true MX2012003514A (es) 2012-04-19

Family

ID=43796491

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003514A MX2012003514A (es) 2009-09-23 2010-09-23 Metodos para tratamiento de inflamaciones.

Country Status (9)

Country Link
EP (1) EP2480579A4 (es)
KR (1) KR20120105429A (es)
CN (1) CN102725311A (es)
AU (1) AU2010298249A1 (es)
BR (1) BR112012006468A2 (es)
CA (1) CA2773978A1 (es)
IN (1) IN2012DN02423A (es)
MX (1) MX2012003514A (es)
WO (1) WO2011038149A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9328174B2 (en) * 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
AU2013262397B2 (en) * 2012-05-17 2017-07-27 Anji Pharmaceuticals Inc. Methods and uses for proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors
TW201605886A (zh) * 2013-11-14 2016-02-16 巴克斯特保健公司 作爲治療標靶的ｍｉｆ
CA3017345A1 (en) 2016-03-11 2017-09-14 Ardea Biosciences, Inc. Cxcr-2 inhibitors for treating crystal arthropathy disorders
AU2019282132A1 (en) 2018-06-05 2020-12-17 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis
US11573228B2 (en) * 2018-12-26 2023-02-07 Colgate-Palmolive Company Biomarkers of neutrophil deregulation as diagnostic for gingivitis
JP2023517616A (ja) * 2020-03-11 2023-04-26 バイオラインアールエックス・リミテッド 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤
WO2021219495A1 (en) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN112656934A (zh) * 2021-01-22 2021-04-16 深圳市图微安创科技开发有限公司 多肽at03在治疗原发性胆汁性胆管炎药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
WO2003072753A2 (en) * 2002-02-27 2003-09-04 Emory University Multimeric binding complexes
CN102174108B (zh) * 2002-03-01 2016-06-29 免疫医疗公司 内在化抗-cd74抗体和使用方法
US7897349B2 (en) * 2003-12-30 2011-03-01 The United States Of America As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (MIF) as marker for urological inflammatory disease
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
BRPI0910259A2 (pt) * 2008-03-20 2015-12-01 Carolus Therapeutics Inc métodos de tratamento de inflamação
WO2010056910A2 (en) * 2008-11-12 2010-05-20 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Also Published As

Publication number Publication date
EP2480579A2 (en) 2012-08-01
CA2773978A1 (en) 2011-03-31
IN2012DN02423A (es) 2015-08-21
EP2480579A4 (en) 2013-07-31
KR20120105429A (ko) 2012-09-25
WO2011038149A2 (en) 2011-03-31
CN102725311A (zh) 2012-10-10
WO2011038149A3 (en) 2011-10-27
BR112012006468A2 (pt) 2016-08-09
AU2010298249A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
MX2012003514A (es) Metodos para tratamiento de inflamaciones.
WO2009117710A3 (en) Methods of treating inflammation
MX2019005289A (es) Composiciones de corticosteroides administradas oralmente.
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
MX2010006823A (es) Metodos para el tratamiento de la gota.
TW200738262A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
WO2010005524A3 (en) Abdominal aortic aneurysms: systems and methods of use
MX2018013333A (es) Composiciones de nucleasas terapeuticas y metodos.
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
RS53467B (en) USE OF AMISULPRID FOR TREATMENT OF Nausea and Vomiting Caused by Chemotherapy
WO2009080800A3 (en) Method for decreasing abdominal girth by administering a bifidobacterium bacteria
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2009016488A3 (en) Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
GB201017889D0 (en) A polymeric nanoparticle
MX2012002855A (es) Terapia de cancer dirigida a celula madre de cancer y resistente a farmaco.
EP2566502A4 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
WO2011116245A3 (en) Methods of treating inflammation
MY161853A (en) Pharmaceutical composition and method for treating hypertension
AU2010298020A8 (en) Combination
WO2011019867A3 (en) Dietary supplements and methods for treating pain and inflammation
WO2008073317A3 (en) Cytarabine for treatment of glioma
TN2011000206A1 (en) Compositions and methods of use soluble thrombomodulin variants